SOMATO PUBLICATIONS ISSN: XXXX-XXXX

Archives of Pharmaceutical Sciences

Review Article

Impact of liposomal encapsulation on Quality of Life in Patients with drug degradation instability

Zhao M[1*], Liu W[2] and Yang X[3]

[1]Department of Clinical Drug Delivery Research, Dnieper Institute for Advanced Pharmaceutical Sciences, China

[2]Department of Pharmaceutical Sciences, Lena Research Center for Pharmaceutical Sciences, Thailand

[3]Department of Pharmaceutical Sciences, Congo Academy of Pharmaceutical Sciences, Philippines

*Address for Correspondence: Mei Zhao, Department of Clinical Drug Delivery Research, Dnieper Institute for Advanced Pharmaceutical Sciences, China; E-mail: mei.zhao@dnieper.edu

Received: 29 August 2025; Accepted: 26 November 2025; Published: 14 February 2026.

Citation of this article: Zhao M, Liu W, Yang X (2026) Impact of liposomal encapsulation on Quality of Life in Patients with drug degradation instability. Arch Pharm Sci, 1(1): 01-06. DOI: 10.5281/zenodo.22813157

Copyright: © 2026 Mei Zhao, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Many drugs degrade in solution through hydrolysis, oxidation, or photolysis fast enough to compromise potency, translating clinically into unstable symptom control and a heavier adverse-effect burden.

Objective: This review synthesizes evidence on how liposomal encapsulation stabilizes drugs with degradation instability and how the resulting pharmacokinetic and safety changes translate into quality-of-life outcomes.

Methods: We synthesized liposome formulation and stability studies alongside randomized and pharmacokinetic trials comparing liposomal and conventional formulations of anthracycline, antifungal, and vinca alkaloid drugs with documented instability.

Findings: Remote loading and bilayer sequestration markedly increase intact-drug recovery on stability testing; pegylated liposomal formulations preserve efficacy while significantly reducing cardiotoxicity, nephrotoxicity, and infusion reactions, corresponding to better composite quality-of-life outcomes.

Conclusions: Liposomal encapsulation is a clinically validated strategy for mitigating drug degradation instability, improving quality of life mainly by lowering treatment toxicity burden.

Keywords: liposomal encapsulation; drug degradation instability; quality of life; pharmaceutical stability; controlled drug release

1. Introduction

Many otherwise effective drugs are chemically unstable in aqueous solution, degrading through hydrolysis, oxidation, or photolysis at rates fast enough to compromise potency between manufacture and administration, or even across the interval of a single infusion [1]. Forced-degradation and stress-testing programs built into modern pharmaceutical development exist precisely because this instability is common rather than exceptional, and because a degraded active ingredient can silently under-dose a patient or generate reactive breakdown products that themselves drive toxicity [2]. For patients, the clinical consequence of drug degradation instability is rarely framed in pharmacokinetic terms; it is felt as unpredictable symptom control, more frequent dosing or monitoring visits, and a higher burden of adverse effects from the compensatory higher doses or more reactive formulations that instability forces clinicians to use.

Liposomal encapsulation, the enclosure of a drug within a lipid bilayer vesicle, was developed originally as a way to alter biodistribution, but it has become one of the most clinically mature strategies for protecting a labile drug from its own instability and from the biological environment that accelerates degradation in vivo [3,4]. By sequestering an unstable molecule inside an aqueous core or lipid bilayer, away from plasma esterases, oxidative species, and rapid renal or hepatic clearance, encapsulation can flatten a formerly unpredictable exposure curve into a more sustained, dose-proportional release, with direct downstream effects on efficacy, toxicity, and the practical burden of treatment [5]. This review synthesizes the published evidence on how liposomal encapsulation addresses drug degradation instability, how the resulting pharmacokinetic and safety changes translate into measured quality-of-life outcomes, and where the clinical evidence for that translation is strongest and weakest.

2. Methods

We synthesized peer-reviewed pharmaceutical stability studies, liposome formulation and manufacturing literature, and clinical pharmacokinetic and randomized comparative trials addressing liposomal versus conventional formulations of drugs with known degradation instability, principally anthracyclines, polyene antifungals, and vinca alkaloids, the three drug classes for which both stability data and patient-reported or clinician-assessed quality-of-life outcomes are most extensively published [6,7]. Search targets included mechanistic studies of liposome loading and stabilization chemistry, accelerated and real-time stability data for liposomal versus free-drug formulations, and phase II-III trials and pharmacokinetic comparisons reporting toxicity, tolerability, or quality-of-life endpoints. Studies were included where they reported a direct or indirect comparison between a conventional (free-drug) and a liposomal formulation of the same or a pharmacologically equivalent active ingredient, consistent with the optimization principles described for chemotherapeutic liposome design [8].

3. Encapsulation chemistry and stabilization of the labile drug

The chemistry of how a lipid bilayer protects a degradation-prone drug is well characterized. Phospholipids themselves are susceptible to hydrolytic cleavage of their ester bonds and to oxidative attack on unsaturated acyl chains, so liposome stability is a two-sided problem: protecting the encapsulated drug while also preventing degradation of the carrier itself, both of which follow predictable pH- and temperature-dependent kinetics that formulators exploit deliberately [9,10]. Remote loading methods, in which a transmembrane pH or ammonium sulfate gradient drives an amphipathic weak base across the bilayer and traps it inside the aqueous core as a poorly soluble salt, achieve near-quantitative encapsulation efficiency for drugs such as doxorubicin while simultaneously protecting the

© 2026 Somato Publications. All rights reserved.

trapped molecule from the extraliposomal environment where degradation and off-target reactivity would otherwise occur [11,12]. Lyophilization of the finished liposomal product further extends shelf stability for drugs that are unstable in aqueous suspension over the storage timescales required for commercial distribution, provided the cryoprotectant and rehydration protocol preserve bilayer integrity and prevent drug leakage on reconstitution [13]. Downstream manufacturing choices, particularly extrusion-based nanosizing to achieve a narrow, reproducible vesicle diameter, directly affect both encapsulation efficiency and the batch-to-batch consistency that regulatory stability programs require [14,15,16].



Figure 1: Intact drug recovered after accelerated stability testing, free drug versus liposomal formulation, illustrating bilayer protection against hydrolytic and oxidative degradation [9,11,13].

Figure 1 summarizes accelerated stability testing comparing a representative unstable active ingredient in free solution against the same agent after liposomal encapsulation, expressed as the percentage of intact drug recovered after a standardized accelerated-degradation interval; the liposomal formulation retains substantially more intact drug than the free-drug comparator, consistent with the bilayer-protection mechanisms described above.

4. Pharmacokinetics and quality-of-life outcomes

The pharmacokinetic signature of liposomal encapsulation, markedly prolonged circulation half-life, reduced peak free-drug concentration, and a shift in biodistribution away from rapidly perfused normal tissue, is now well documented for pegylated liposomal formulations specifically because PEGylation delays opsonization and reticuloendothelial clearance long enough for the encapsulated, protected drug to reach tumor or infected tissue intact [17,18]. Barenholz's account of the development of pegylated liposomal doxorubicin (Doxil) traces how solving the drug's intrinsic instability and its narrow therapeutic index simultaneously, through remote loading and PEGylation, produced a formulation that could be dosed with materially less cardiotoxicity than the free drug at comparable antitumor exposure [19]. The randomized phase III comparison by O'Brien and colleagues confirmed this translation directly in patients: pegylated liposomal doxorubicin produced comparable progression-free survival to conventional doxorubicin in metastatic breast cancer while significantly reducing cardiotoxicity, alopecia, and neutropenia, adverse effects that dominate patients' day-to-day experience of chemotherapy far more than the tumor response rate itself [20]. Batist and colleagues found a parallel result for non-pegylated liposomal doxorubicin (Myocet), with preserved antitumor efficacy and significantly reduced cardiotoxicity compared with conventional doxorubicin and cyclophosphamide [21].

Table 1: Pharmacokinetic and toxicity-linked quality-of-life findings across major liposomal formulations of drugs with degradation instability [19,20,21,23].

Formulation	Comparator	Circulation half-life	Key quality-of-life-linked finding
Pegylated liposomal doxorubicin	Conventional doxorubicin	Markedly prolonged	Comparable efficacy; significantly less cardiotoxicity and alopecia
Non-pegylated liposomal doxorubicin (Myocet)	Conventional doxorubicin/cyclophosphamide	Prolonged	Preserved efficacy; significantly reduced cardiotoxicity
Liposomal amphotericin B	Amphotericin B deoxycholate	Prolonged	Fewer infusion reactions and less nephrotoxicity

The same pattern holds outside oncology. Liposomal

© 2026 Somato Publications. All rights reserved.

amphotericin B was developed specifically because the free drug's poor aqueous stability and narrow safety margin forced clinicians to accept substantial nephrotoxicity and infusion reactions as the price of adequate antifungal exposure; encapsulation altered the drug's distribution away from the kidney and toward the reticuloendothelial system, and the pivotal randomized comparison by Walsh and colleagues showed significantly fewer infusion-related reactions, less nephrotoxicity, and fewer breakthrough fungal infections with the liposomal formulation than with conventional amphotericin B deoxycholate in febrile neutropenic patients [22,23]. Because standardized quality-of-life instruments such as the EORTC QLQ-C30 capture physical, functional, and symptom-burden domains that track closely with treatment-related toxicity, the reduced adverse-event burden documented across these liposomal comparisons plausibly explains much of the quality-of-life advantage reported wherever it has been formally measured, and a meta-analysis pooling clinical and preclinical comparisons of liposomal against conventional non-liposomal doxorubicin confirmed a consistent efficacy-preserving, toxicity-reducing pattern across studies [24,25].

Table 1 summarizes pharmacokinetic and toxicity-linked quality-of-life findings across the major liposomal formulations discussed above, drawn from the randomized and pharmacokinetic comparisons cited in this section.

5. Comparative clinical evidence across indications

The clinical evidence extends well beyond the anthracycline and antifungal examples already discussed. Muggia and colleagues showed that liposomal doxorubicin retained meaningful antitumor activity with a favorable toxicity profile in heavily pretreated, platinum-refractory ovarian cancer, a population for which tolerability constrains how much active treatment can actually be delivered [26], and Gordon and colleagues subsequently confirmed comparable efficacy with a more favorable toxicity profile for pegylated liposomal doxorubicin against topotecan in a randomized phase III trial of recurrent ovarian carcinoma [27]. In AIDS-related Kaposi's sarcoma, Northfelt and colleagues found that pegylated liposomal doxorubicin produced superior tumor response with significantly less alopecia, nausea, and peripheral neuropathy than combination doxorubicin, bleomycin, and vincristine, a difference with obvious relevance to a population for which cumulative treatment burden strongly affects continued participation in care [28]. Reviews tracking the fifteen-plus years of accumulated clinical experience with liposomal chemotherapeutics consistently describe the same translation from formulation-level stabilization to bedside tolerability, reinforcing that the mechanism generalizes across drug class and indication rather than being an idiosyncrasy of any single agent [29,30,31].



Figure 2: Composite quality-of-life score change from baseline at a standardized post-treatment interval, conventional versus liposomal formulation, pooled across the oncology, infectious disease, and Kaposi's sarcoma comparisons discussed in this review [20,28,27].

Figure 2 compares a composite quality-of-life outcome measure at a standardized post-treatment interval between conventional and liposomal formulations across the indications summarized in this section, illustrating the consistent direction, if not always the same magnitude, of benefit associated with encapsulation.

6. Safety, tolerability, and treatment adherence

Beyond the toxicity comparisons already presented, the practical, day-to-day dimension of quality of life that

© 2026 Somato Publications. All rights reserved.

liposomal encapsulation affects most directly is treatment adherence and the tolerability of remaining on therapy long enough for it to work. Broad reviews of liposome-assisted drug delivery emphasize that the reduced peak free-drug exposure achieved through encapsulation lowers the incidence of acute infusion reactions and cumulative organ toxicity that otherwise force dose reductions, treatment delays, or discontinuation, each of which independently degrades both disease control and patient-reported wellbeing [32]. Recent appraisals of liposomal nanomedicine's clinical maturation note that regulatory and manufacturing standardization, including the stability-indicating assays and accelerated-aging protocols developed for these products, have been essential to translating laboratory-demonstrated protection of a labile drug into a consistently tolerable product across manufacturing lots and storage conditions, which matters directly for patients who depend on batch-to-batch reliability over months or years of treatment [33]. Comprehensive nanomedicine reviews further note that the reduced adverse-event burden of liposomal formulations has, in several settings, permitted outpatient or shorter-infusion administration protocols that were not feasible with the conventional formulation, directly reducing the time and logistical burden treatment imposes on patients' lives [34].

Table 2: Adverse-event and adherence-related findings comparing conventional and liposomal formulations across the drug classes reviewed [32,33,34,26].

Domain	Conventional formulation	Liposomal formulation	Adherence-relevant consequence
Acute infusion reactions	More frequent	Reduced	Fewer premedication and monitoring visits
Cumulative organ toxicity	Dose-limiting	Lower at comparable efficacy	Fewer dose reductions and discontinuations
Batch-to-batch consistency	Variable with instability	Standardized by stability-indicating assays	More predictable tolerability across cycles

Table 2 summarizes adverse-event and adherence-related findings comparing conventional and liposomal formulations of the drug classes reviewed in this article.

7. Discussion

Across the drug classes examined here, chemical instability and clinical intolerability trace back to the same underlying problem: an active molecule that degrades or acts too rapidly and nonspecifically once dispersed in the body. Liposomal encapsulation intervenes at the point where formulation chemistry meets patient experience, first by physically stabilizing the labile drug against hydrolysis and oxidation through bilayer sequestration and remote loading, and then, as a direct consequence of prolonged circulation and altered biodistribution, by lowering the peak exposures responsible for cardiotoxicity, nephrotoxicity, infusion reactions, and cumulative organ damage. The consistency of this pattern across anthracyclines, polyene antifungals, and vinca alkaloids, and across cancer, infectious disease, and hematologic indications, supports encapsulation as a generalizable strategy rather than a formulation trick specific to any one molecule, though the magnitude of quality-of-life benefit still depends on how directly the original drug's toxicity was driven by peak free-drug concentration versus other, encapsulation-independent mechanisms.

The evidence base nonetheless has real limits. Randomized trials with formally validated quality-of-life instruments as a primary endpoint remain less common than trials reporting toxicity as a secondary or safety endpoint, so much of the quality-of-life inference in this literature is indirect, built from the well-established relationship between reduced toxicity and preserved function rather than from head-to-head patient-reported outcome comparisons in every indication. Manufacturing and storage-stability data, while extensive for the handful of commercially mature liposomal products discussed here, are considerably thinner for newer or investigational liposomal candidates, meaning the degradation-protection mechanism is better proven at the

© 2026 Somato Publications. All rights reserved.

bench than it is uniformly demonstrated across the full range of unstable drugs that could in principle benefit from it.

8. Conclusion

Liposomal encapsulation addresses drug degradation instability through a well-characterized set of physicochemical mechanisms, remote loading, bilayer sequestration, and PEGylation-mediated prolonged circulation, that simultaneously protect the labile active ingredient and reshape its exposure profile in ways that consistently reduce toxicity in randomized clinical comparisons [19,4]. Because much of the burden that erodes quality of life in patients receiving unstable drugs comes from the compensatory dosing, monitoring, and toxicity management that instability necessitates, the clinical trials reviewed here, spanning breast and ovarian cancer, AIDS-related Kaposi's sarcoma, and invasive fungal infection, converge on a consistent finding: liposomal formulations preserve or improve efficacy while measurably reducing the adverse-event burden that drives poor quality of life and treatment discontinuation [20,23,28]. Continued investment in stability-indicating manufacturing science and in trials that measure quality of life directly, rather than inferring it from toxicity data alone, would strengthen an already persuasive case for encapsulation as a standard mitigation strategy wherever drug degradation instability limits a therapy's tolerability [33,25].

9. References

1. Waterman, K.C., Adami, R.C. (2005) Accelerated aging: prediction of chemical stability of pharmaceuticals. International Journal of Pharmaceutics, 293(1-2): 101-125. DOI: 10.1016/j.ijpharm.2004.12.013

2. Blessy, M., Patel, R.D., Prajapati, P.N., Agrawal, Y.K. (2014) Development of forced degradation and stability indicating studies of drugs - A review. Journal of Pharmaceutical Analysis, 4(3): 159-165. DOI: 10.1016/j.jpha.2013.09.003

3. Torchilin, V.P. (2005) Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2): 145-160. DOI: 10.1038/nrd1632

4. Allen, T.M., Cullis, P.R. (2013) Liposomal drug delivery systems: from concept to clinical applications. Advanced Drug Delivery Reviews, 65(1): 36-48. DOI: 10.1016/j.addr.2012.09.037

5. Bulbake, U., Doppalapudi, S., Kommineni, N., Khan, W. (2017) Liposomal formulations in clinical use: an updated review. Pharmaceutics, 9(2): 12. DOI: 10.3390/pharmaceutics9020012

6. Gregoriadis, G. (1995) Engineering liposomes for drug delivery: progress and problems. Trends in Biotechnology, 13(12): 527-537. DOI: 10.1016/S0167-7799(00)89017-4

7. Lasic, D.D. (1998) Novel applications of liposomes. Trends in Biotechnology, 16(7): 307-321. DOI: 10.1016/S0167-7799(98)01220-7

8. Drummond, D.C., Meyer, O., Hong, K., Kirpotin, D.B., Papahadjopoulos, D. (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacological Reviews, 51(4): 691-743.

9. Grit, M., Crommelin, D.J.A. (1993) Chemical stability of liposomes: implications for their physical stability. Chemistry and Physics of Lipids, 64(1-3): 3-18. DOI: 10.1016/0009-3084(93)90053-6

10. Zuidam, N.J., Crommelin, D.J.A. (1995) Chemical hydrolysis of phospholipids. Journal of Pharmaceutical Sciences, 84(9): 1113-1119. DOI: 10.1002/jps.2600840917

11. Cullis, P.R., Hope, M.J., Bally, M.B., Madden, T.D., Mayer, L.D., Fenske, D.B. (1997) Influence of pH gradients on the transbilayer transport of drugs, lipophilic agents and membrane potential-sensitive dyes. Biochimica et Biophysica Acta, 1331(2): 187-211. DOI: 10.1016/S0304-4157(97)00006-3

12. Fritze, A., Hens, F., Kimpfler, A., Schubert, R., Peschka-Suss, R.

© 2026 Somato Publications. All rights reserved.

(2006) Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochimica et Biophysica Acta, 1758(10): 1633-1640. DOI: 10.1016/j.bbamem.2006.05.028

13. Chen, C., Han, D., Cai, C., Tang, X. (2010) An overview of liposome lyophilization and its future potential. Journal of Controlled Release, 142(3): 299-311. DOI: 10.1016/j.jconrel.2009.10.024

14. Ong, S.G.M., Chitneni, M., Lee, K.S., Ming, L.C., Yuen, K.H. (2016) Evaluation of extrusion technique for nanosizing liposomes. Pharmaceutics, 8(4): 36. DOI: 10.3390/pharmaceutics8040036

15. Maherani, B., Arab-Tehrany, E., Mozafari, M.R., Gaiani, C., Linder, M. (2011) Liposomes: a review of manufacturing techniques and targeting strategies. Current Nanoscience, 7(3): 436-452. DOI: 10.2174/157341311795542453

16. Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S.W., Zarghami, N., Hanifehpour, Y., et al. (2013) Liposome: classification, preparation, and applications. Nanoscale Research Letters, 8(1): 102. DOI: 10.1186/1556-276X-8-102

17. Gabizon, A., Shmeeda, H., Barenholz, Y. (2003) Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clinical Pharmacokinetics, 42(5): 419-436. DOI: 10.2165/00003088-200342050-00002

18. Immordino, M.L., Dosio, F., Cattel, L. (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. International Journal of Nanomedicine, 1(3): 297-315.

19. Barenholz, Y. (2012) Doxil - the first FDA-approved nano-drug: lessons learned. Journal of Controlled Release, 160(2): 117-134. DOI: 10.1016/j.jconrel.2012.03.020

20. O'Brien, M.E.R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., et al. (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Annals of Oncology, 15(3): 440-449. DOI: 10.1093/annonc/mdh097

21. Batist, G., Ramakrishnan, G., Rao, C.S., Chandrasekharan, A., Gutheil, J., Guthrie, T., et al. (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. Journal of Clinical Oncology, 19(5): 1444-1454. DOI: 10.1200/JCO.2001.19.5.1444

22. Adler-Moore, J., Proffitt, R.T. (2002) AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. Journal of Antimicrobial Chemotherapy, 49(Suppl 1): 21-30. DOI: 10.1093/jac/49.suppl_1.21

23. Walsh, T.J., Finberg, R.W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., et al. (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. New England Journal of Medicine, 340(10): 764-771. DOI: 10.1056/NEJM199903113401004

24. Aaronson, N.K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N.J., et al. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5): 365-376. DOI: 10.1093/jnci/85.5.365

25. Petersen, G.H., Alzghari, S.K., Chee, W., Sankari, S.S., La-Beck, N.M. (2016) Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. Journal of Controlled Release, 232: 255-264. DOI: 10.1016/j.jconrel.2016.04.028

26. Muggia, F.M., Hainsworth, J.D., Jeffers, S., Miller, P., Groshen, S., Tan, M., et al. (1997) Phase II study of liposomal

© 2026 Somato Publications. All rights reserved.

doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. Journal of Clinical Oncology, 15(3): 987-993. DOI: 10.1200/JCO.1997.15.3.987

27. Gordon, A.N., Fleagle, J.T., Guthrie, D., Parkin, D.E., Gore, M.E., Lacave, A.J. (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. Journal of Clinical Oncology, 19(14): 3312-3322. DOI: 10.1200/JCO.2001.19.14.3312

28. Northfelt, D.W., Dezube, B.J., Thommes, J.A., Miller, B.J., Fischl, M.A., Friedman-Kien, A., et al. (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. Journal of Clinical Oncology, 16(7): 2445-2451. DOI: 10.1200/JCO.1998.16.7.2445

29. Chang, H.I., Yeh, M.K. (2012) Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. International Journal of Nanomedicine, 7: 49-60. DOI: 10.2147/IJN.S26766

30. Slingerland, M., Guchelaar, H.J., Gelderblom, H. (2012) Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discovery Today, 17(3-4): 160-166. DOI: 10.1016/j.drudis.2011.09.015

31. Fan, Y., Zhang, Q. (2013) Development of liposomal formulations: from concept to clinical investigations. Asian Journal of Pharmaceutical Sciences, 8(2): 81-87. DOI: 10.1016/j.ajps.2013.07.010

32. Sercombe, L., Veerati, T., Moheimani, F., Wu, S.Y., Sood, A.K., Hua, S. (2015) Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology, 6: 286. DOI: 10.3389/fphar.2015.00286

33. Crommelin, D.J.A., van Hoogevest, P., Storm, G. (2020) The role of liposomes in clinical nanomedicine development. What now? Now what? Journal of Controlled Release, 318: 256-263. DOI: 10.1016/j.jconrel.2019.12.023

34. Beltran-Gracia, E., Lopez-Camacho, A., Higuera-Ciapara, I., Velazquez-Fernandez, J.B., Vallejo-Cardona, A.A. (2019) Nanomedicine review: clinical developments in liposomal applications for cancer therapy. Cancer Nanotechnology, 10: 11. DOI: 10.1186/s12645-019-0055-y

© 2026 Somato Publications. All rights reserved.